A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
Completed
Bristol-Myers Squibb
Phase 3
2001-12-01
The purpose of this clinical research study is to assess the safety effectiveness of
entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B
infection who are hepatitis B e antigen positive.
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
Completed
Bristol-Myers Squibb
Phase 3
2001-11-01
The purpose of this clinical research study is to assess the safety and effectiveness of
entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B
infection who are hepatitis B e antigen negative.
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
Completed
Bristol-Myers Squibb
Phase 3
2002-01-01
The purpose of this clinical research study is to assess the safety and effectiveness of
switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
Completed
Bristol-Myers Squibb
Phase 2/Phase 3
2002-09-01
The purpose of this clinical research study is to assess the safety and effectiveness of
entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis
B infection who are co-infected with HIV.
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
Completed
Bristol-Myers Squibb
Phase 3
2003-08-01
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg
QD in patients who have chronic hepatitis B infection and hepatic decompensation. The
patients are treated for 96 weeks after the last subject is randomized.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
